Publication date: Jul 10, 2024
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates advanced prognostic tools to anticipate disease progression and optimize patient outcomes. This study evaluates the predictive value and diagnostic potential of interleukins interleukin (IL) IL-10, IL-17A, IL1-β, IL-6, chemokine ligand (CXCL), and Monocyte Chemotactic Protein (MCP) for severe coronavirus disease 2019 (COVID-19) and COVID-19 mortality, aiming to correlate cytokine levels with disease severity. Conducted from January 2023 to January 2024, this prospective cohort study involved patients hospitalized with moderate and severe COVID-19 from Romania. This study analyzed statistically significant predictors of severe COVID-19 outcomes. IL-6 and MCP emerged as significant, with hazard ratios (HRs) of 2. 35 (95% confidence interval (CI): 1. 54-3. 59, p = 0. 014) and 2. 05 (95% CI: 1. 22-3. 45, p = 0. 007), respectively. Compound scores integrating multiple inflammatory markers also demonstrated predictive value; Compound Score 2 had an HR of 2. 23 (95% CI: 1. 35-3. 68, p = 0. 002), surpassing most single markers in association with severe disease. Notably, interleukins IL-10 and IL-1β did not show significant associations with disease severity. This study underscores the importance of IL-6 and MCP as robust predictors of severe COVID-19, substantiating their role in clinical assessments to foresee patient deterioration. The utility of compound scores in enhancing predictive accuracy suggests a composite approach may be more effective in clinical settings.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Biomedicines | COVID-19 |
| Disease | inflammation |
| Romania | respiratory infections |
| SARS-CoV-2 |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Interleukin-10 |
| disease | MESH | COVID-19 |
| disease | VO | Severe acute respiratory syndrome coronavirus 2 |
| disease | MESH | disease progression |
| disease | VO | effective |
| disease | MESH | Respiratory Diseases |
| disease | MESH | Infectious Diseases |
| disease | MESH | respiratory infections |
| disease | MESH | inflammation |
| disease | VO | vaccination |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | fatal outcomes |
| disease | MESH | complications |
| disease | MESH | acute respiratory distress syndrome |
| disease | MESH | sepsis |
| disease | MESH | thromboembolism |
| disease | MESH | death |
| disease | MESH | infections |
| disease | IDO | blood |
| disease | VO | organ |
| drug | DRUGBANK | Oxygen |
| disease | MESH | Co infection |
| disease | MESH | influenza |
| disease | MESH | bacterial pneumonia |
| drug | DRUGBANK | Edetic Acid |
| disease | IDO | assay |
| disease | IDO | process |
| disease | MESH | pneumonia |
| drug | DRUGBANK | Medical air |
| disease | MESH | respiratory failure |
| disease | MESH | septic shock |
| disease | VO | USA |
| drug | DRUGBANK | Saquinavir |
| drug | DRUGBANK | L-Alanine |
| drug | DRUGBANK | Fibrinogen Human |